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Abstract: Low HDL-cholesterol ( 1.02 mmol/L [40 mg/dL] in men or  1.29 mmol/L [50 mg/dL] 
in women) occurs in about one-third of European patients with dyslipidemia and is an independent 
cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high total-
cholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality 
beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective 
means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event 
rates signiﬁ  cantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily 
means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, 
long-term increases in HDL-cholesterol with additional useful beneﬁ  ts on triglycerides, LDL-
cholesterol, and lipid sub-proﬁ  les. The NAUTILUS study demonstrated the beneﬁ  cial efﬁ  cacy and 
tolerability proﬁ  les of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® 
is ﬂ  ushing, which infrequently causes treatment discontinuation and which usually subsides over 
continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment 
with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery 
disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular 
outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low 
HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.
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Introduction
Cardiovascular disease remains the main cause of mortality in developed nations, 
and an increasing tendency towards urbanization, adoption of western lifestyles, and 
obesity threatens a substantial future burden of cardiovascular morbidity and mortality 
in developing nations (Dominguez et al 2006; Raymond et al 2006). It is necessary to 
maximize the use of all cardiovascular management strategies to address this challenge 
adequately. Dyslipidemia remains an important source of elevated cardiovascular risk 
and is heterogeneous in presentation, with elevated ApoB-containing lipoproteins (eg, 
LDL-cholesterol) and/or low HDL-cholesterol commonly observed. Moreover, patients 
with conditions often associated with insulin resistance, such as type 2 diabetes, the 
metabolic syndrome, or abdominal obesity, often present with a characteristic dys-
lipidemic phenotype that includes low HDL-cholesterol in the presence of normal or 
near-normal LDL-cholesterol (Niskanen et al 1998; Goldberg 2001; Hansel et al 2004). 
This phenotype predicts an increased risk of adverse cardiovascular outcomes. This is 
caused by the accumulation of triglyceride-rich remnants and by the more atherogenic 
small LDL-particles associated with the metabolic syndrome and, on the other hand, Vascular Health and Risk Management 2007:3(4) 468
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by the reduced cardiovascular protection resulting from low 
levels of HDL-cholesterol (Niskanen et al 1998). 
In the prevention of cardiovascular disease, even 
intensive intervention with a statin, achieving levels of 
LDL-cholesterol well below those recommended by current 
cardiovascular management guidelines, has failed to reduce 
cardiovascular event rates by more than about 20%–40% 
relative to placebo (reviewed by Kastelein 2005). Since 
HDL-cholesterol is an important cardiovascular risk factor, 
addressing both hypercholesterolemia and low HDL-
cholesterol is a rational clinical strategy for patients with 
these lipid abnormalities. Strategies are available to achieve 
these twin goals: HMG-CoA reductase inhibitors (statins) 
provide effective control of LDL-cholesterol and nicotinic 
acid (known as niacin in the USA) is the most powerful agent 
available for the correction of low HDL-cholesterol (Expert 
Panel 2001). Niaspan® is a once-daily, prolonged-release 
formulation of nicotinic acid which is indicated in many 
areas for the correction of low HDL-cholesterol. Current 
US and European management guidelines, however, focus 
strongly on control of LDL-cholesterol as the primary focus 
of cardiovascular care (Expert Panel 2001; Third Joint Task 
Force 2003). Accordingly, this review not only summarizes 
the therapeutic proﬁ  le of Niaspan®, but also discusses the 
substantial evidence base supporting the clinical potential 
of correcting low HDL-cholesterol.
Why we should correct low 
HDL-cholesterol
Low HDL-cholesterol is an independent 
cardiovascular risk factor
The Framingham Study identiﬁ  ed low HDL-cholesterol 
as an independent risk factor for adverse cardiovascular 
outcomes more than three decades ago (Gordon et al 1977). 
This landmark study deﬁ  ned a signiﬁ  cant association (p   
0.001) between low HDL-cholesterol and a range of car-
diovascular endpoints in men and women during 4 years of 
follow-up. Importantly, the increased cardiovascular risk 
associated with low HDL-cholesterol was greater than that 
associated with elevated LDL-cholesterol, and persisted 
after adjustment for other lipid parameters and cardiovascu-
lar risk factors. Further analyses from this landmark study, 
involving up to 12 years of follow-up, have conﬁ  rmed that 
low HDL-cholesterol increases cardiovascular risk over the 
long term, with an approximate 4-fold increase in the risk 
of cardiovascular or coronary death, and an approximate 
doubling of the risk of death from any cause (Castelli et 
al 1986; Wilson et al 1988). The 10-year Atherosclerosis 
Risk in Communities (ARIC) study also demonstrated an 
independent and signiﬁ  cant inﬂ  uence of low HDL-choles-
terol on cardiovascular risk in a North American population 
(Sharrett et al 2001). A pooled analysis of Framingham 
and three other major North American trials (the Lipid 
Research Clinics Prevalence Mortality Follow-up Study, the 
Coronary Primary Prevention Trial and the Multiple Risk 
Factor Intervention Trial) showed that for each decrease 
in HDL-cholesterol of 0.03 mmol/L (1 mg/dL), the risk of 
coronary heart disease increased by 2% in men and by 3% 
in women (Gordon et al 1989).
Similar associations between low HDL-cholesterol and 
cardiovascular risk hold in other populations. A large obser-
vational study in Germany, the PROspective CArdiovascular 
Münster (PROCAM) Study, showed that subjects with low 
HDL-cholesterol had an approximately four-fold increase in 
the risk of coronary heart disease, compared with subjects 
with normal HDL-cholesterol levels, consistent with the 
results from Framingham (Assmann et al 1996). A study in 
a population of German type 2 diabetes patients undergoing 
coronary angiography used factor analysis to determine the 
elements of the lipid proﬁ  le that were most signiﬁ  cantly 
associated with adverse cardiovascular outcomes during 
subsequent follow up (Drexel et al 2005). Factor analysis 
is a statistical technique that analyses the effects of a large 
number of variables and expresses their overall effects in 
terms of a smaller number of key variables, termed factors. 
In this way, factor analysis reveals the underlying driving 
forces behind complex phenomena. This analysis identiﬁ  ed 
two distinct factors: one, related to HDL-cholesterol, was 
signiﬁ  cantly associated with coronary atherosclerosis, while 
another factor, related to LDL-cholesterol, was not. 
A study in the UK demonstrated a signiﬁ  cant inverse 
association between the level of HDL-cholesterol and the 
risk of ischemic heart disease, but found that this was not 
independent of other cardiovascular risk factors (Pocock 
et al 1989). However, a re-analysis of these data in a 
manner consistent with the US studies described above 
(in terms of covariates used) revealed a consistent inverse 
relationship between HDL-cholesterol levels and coronary 
risk (Gordon et al 1989). A further study from the UK 
found an independent inverse relationship between levels of 
HDL-cholesterol (particularly the HDL2 sub-fraction) and 
the severity of angiographically deﬁ  ned coronary stenoses 
(Miller et al 1981). The UK Prospective Diabetes Study 
identiﬁ  ed HDL-cholesterol as the second most important 
risk factor for coronary artery disease during 10 years of Vascular Health and Risk Management 2007:3(4) 469
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follow-up of newly-diagnosed type 2 diabetes patients 
(Turner et al 1998). In a population of more than 8000 
Israeli subjects without prior coronary disease followed for 
21 years, low HDL-cholesterol ( 0.9 mmol/L [35 mg/dL]) 
was associated with an increase in coronary mortality of 
about 20%–25% (Goldbourt et al 1997). Finally, the large, 
international Interheart case-control study found that a high 
ApoB:ApoAI ratio accounted for more than half of the 
population-attributable risk of a ﬁ  rst myocardial infarction 
(Yusuf et al 2004). 
It is important to note that the prognostic signiﬁ  cance 
of low HDL-cholesterol is similar whether or not LDL-
cholesterol is elevated. Data from the Framingham study 
suggest that, on average, the risk of coronary heart disease 
in a patient with elevated LDL-cholesterol (5.7 mmol/L 
[220 mg/dL]) and normal HDL-cholesterol (1.2 mmol/L 
[45 mg/dL]) is comparable with the risk in a patient with 
well-controlled LDL-cholesterol (2.6 mmol/L [100 mg/
dL]) and low HDL-cholesterol (0.6 mmol/L [25 mg/dL]) 
(Gordon et al 1977; Castelli et al 1988). Moreover, the 
long-term observational study in Israeli subjects stratiﬁ  ed 
patients on the basis of their levels of HDL-cholesterol and 
total cholesterol (Goldbourt et al 1997). High cholesterol 
( 5.2 mmol/L [213 mg/dL]) increased the risk of death 
from coronary heart disease, as would be expected; never-
theless, the excess risk associated with low HDL-cholesterol 
( 0.9 mmol/L [35 mg/dL]) was essentially the same in the 
high- and low-cholesterol groups (Figure 1).
High prevalence of low HDL-cholesterol 
despite lipid-modifying intervention
Prevalence estimates from various countries suggest a substan-
tial prevalence of low HDL-cholesterol. Data from the PRO-
CAM study demonstrated a prevalence of low HDL-cholesterol 
( 0.9 mmol/L [35 mg/dL] for men and  1.2 mmol/L [45 
mg/dL] for women) of 13%–16% in men and 18%–20% in 
women, depending on age (Assmann et al 1996). Moreover, a 
markedly higher prevalence of low HDL-cholesterol was ob-
served in patients with coronary heart disease (45.2%) relative 
to those without (16.1%) (Assmann et al 1996). Analysis of data 
from general populations of 5 European countries showed that 
HDL-cholesterol  0.90 mmol/L (35 mg/dL) in men or  1.01 
mmol/L ( 39 mg/dL) in women was present in 7%–24% of 
subjects (Balkau et al 2002). Data from the National Health 
and Nutrition Examination Survey in the USA demonstrated 
an age-adjusted prevalence of HDL-cholesterol  1.02 mmol/L 
(40 mg/dL) in men of 35.2% and  1.29 mmol/L (50 mg/dL) 
in women of 39.3% (Ford et al 2002). While these data were 
sufﬁ  cient to arouse concern, differences in the deﬁ  nitions of low 
HDL-cholesterol between studies, and different survey method-
ologies and recruitment criteria precluded the quantiﬁ  cation of 
the magnitude of the problem posed by low HDL-cholesterol. 
The Pan-European Survey of HDL-cholesterol was designed 
to address this problem by generating a reliable estimate of the 
prevalence of low HDL-cholesterol in patients being managed 
for dyslipidemia across 11 countries in Europe (Bruckert et al 
2005a, b). Low HDL-cholesterol was deﬁ  ned as a level below 
1.03 mmol/L (40 mg/dL) in men and 1.29 mmol/L (50 mg/dL) in 
women, in a manner consistent with cardiovascular management 
guidelines. In total, 8545 patients were included in the analysis; 
about one-third of patients had low HDL-cholesterol, and about 
one-ﬁ  fth of patients had a potentially atherogenic combination 
of low HDL-cholesterol and elevated triglycerides (Table 1). 
Importantly, the prevalence of low HDL-cholesterol was similar 
whether or not patients were being actively treated for dyslip-
idemia (mainly with statins). A further analysis in 3866 type 2 
diabetes patients within the survey population revealed a higher 
prevalence of low HDL-cholesterol in this population (45%) 
(Bruckert et al 2007). These data demonstrate that low HDL-
cholesterol is not only prevalent among the general population 
of patients with dyslipidemia, but is under-treated.
Correcting low HDL-cholesterol 
improves cardiovascular outcomes
A number of studies have demonstrated clinically 
significant cardiovascular benefits from pharmacologic 
Figure 1 Adjusted coronary heart disease mortality rates according to HDL-cho-
lesterol and LDL-cholesterol levels during 21 years of follow-up in 8586 Israeli men 
without coronary heart disease at baseline. Cut-off values to deﬁ  ne low/high lipid 
levels were 0.9 mmol/L for HDL-cholesterol and 5.2 mmol/L for total-cholesterol. 
RR: risk ratios compared with corresponding low HDL-cholesterol group (adjusted 
for age, systolic blood pressure, smoking, and diabetes). Drawn from data presented 
by Goldbourt et al (1997). Vascular Health and Risk Management 2007:3(4) 470
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intervention to increase levels of HDL-cholesterol in 
patients with coronary artery disease. Again, this 
knowledge has been available for more than 3 decades, 
since the demonstration of reduced all-cause mortal-
ity in hypercholesterolemic patients randomized to 
receive immediate-release nicotinic acid or placebo in 
the Coronary Drug Project (CDP) in 1975 (CDP 1975). 
A re-analysis of the data from the CDP has shown that 
the cardiovascular benefit arising from nicotinic acid 
was still present 15 years after the conclusion of the 
trial, ie, 9 years after the end of double-blind follow-up 
within the study (Canner et al 1986). Other new analyses 
from this trial have demonstrated that the benefit from 
nicotinic acid extended to subgroups of patients with 
the metabolic syndrome or dysglycemia (Canner et al 
2005, 2006). Nicotinic acid also improves outcomes 
when combined with a statin: the HDL Atherosclerosis 
Treatment Study (HATS) demonstrated a 90% relative 
risk reduction vs placebo in a composite cardiovascular 
endpoint (death, myocardial infarction, stroke or revas-
cularization) (Brown et al 2001). A beneficial effect on 
atherosclerosis progression measured by angiography 
was observed in HATS, and in other trials evaluating 
immediate-release nicotinic acid-based combination 
regimens, consistent with the observed outcome ben-
efits described above (Brown et al 1990; Kane et al 
1990; Whitney et al 2005). Intervention trials using a 
fibrate to increase HDL-cholesterol have also yielded 
significant anti-atherosclerotic benefits or improvements 
in cardiovascular event rates (Frick et al 1987; Cashin-
Hemphill et al 1990; Rubins et al 1999). The Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) 
study, a randomized trial of fenofibrate vs. placebo in 
patients with type 2 diabetes, did not yield a significant 
reduction in cardiovascular event rates (Keech et al 
2005). However, while there was a substantial reduction 
in triglycerides in the fibrate group at study end, there 
was essentially no effect on HDL-cholesterol. Therefore, 
the negative outcome of this trial does not diminish the 
status of low HDL-cholesterol as a cardiovascular risk 
factor.
The therapeutic rationale 
for Niaspan®
The information presented in the previous section clearly 
supports the principle of intervention to correct low HDL-
cholesterol. US cardiovascular management guidelines com-
pare the efﬁ  cacy of different lipid-modifying treatments and 
identify nicotinic acid as the most potent agent available for 
this purpose (Expert Panel 2001). Perceived drawbacks to the 
use of nicotinic acid have limited its use in routine clinical 
practice, however, including concern over a high incidence 
of ﬂ  ushing, potential for hepatotoxicity and exacerbation of 
dysglycemia. 
The therapeutic profile of formulations of nicotinic 
acid depends on its metabolism, which proceeds via two 
distinct biochemical pathways (Pieper 2002). The ﬁ  rst is a 
pathway with high afﬁ  nity, but a low capacity, for nicotinic 
acid which is linked to hepatotoxicity and the second is a 
low-afﬁ  nity but high capacity pathway, which is linked to 
ﬂ  ushing. An oral dose of immediate-release nicotinic acid 
causes a large but relatively brief surge in plasma nicotinic 
acid levels. This saturates the low capacity pathway, and a 
relatively high ﬂ  ux through the second pathway causes the 
ﬂ  ushing commonly observed with nicotinic acid. Previous 
attempts at the development of slow-release nicotinic acid 
preparations, with consequently lower plasma nicotinic acid 
concentrations, reduced the potential for ﬂ  ushing, but led to 
more metabolism via the low-capacity pathway over a longer 
period of time. This resulted in unacceptable hepatotoxicity 
(Dalton and Berry 1992). 
Niaspan® was designed to deliver nicotinic acid at a 
rate intermediate between the immediate release and earlier 
sustained-release formulations, and delivers the drug over a 
period of approximately 8–12 hours (Pieper 2002). In this 
way, Niaspan® was intended to minimize the potential of 
Table 1 Prevalence of low HDL-cholesterol in the Pan-European Survey of HDL-cholesterol (Bruckert et al 2005a) 
    Receiving lipid-modifying treatment  No lipid-modifying treatment
Low HDL-cholesterol (%)   
 Men  32.5  34.4
 Women  39.9  38.5
Low HDL-cholesterol and high triglycerides (%) 
 Men  21.2  26.3
 Women  24.9  26.9
Notes: Low HDL-cholesterol:  1.03 mmol/L (men),  1.29 mmol/L (women); high triglycerides:  1.69 mmol/L (men and women).Vascular Health and Risk Management 2007:3(4) 471
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both hepatotoxicity and ﬂ  ushing. The efﬁ  cacy safety and 
tolerability proﬁ  les of Niaspan® are discussed in detail in the 
following section.
Lipid-modifying efﬁ  cacy of Niaspan®
Niaspan® administered as monotherapy
The effects of Niaspan® on HDL-cholesterol are essentially 
identical to those of immediate-release nicotinic acid. This 
was demonstrated by a double-blind clinical trial in patients 
with primary dyslipidemia randomized to receive once-daily 
Niaspan® 1500 mg (n = 76), immediate-release nicotinic acid 
1500 mg (n = 74) or placebo (n = 73) for 8 weeks (Knopp 
et al 1998). Average percentage changes in HDL-cholesterol 
in the intention-to-treat efﬁ  cacy analysis at 8 weeks were 
18.2% for Niaspan®, 18.7% for immediate-release nicotinic 
acid and 0.4% for placebo (p   0.05 vs either nicotinic acid 
formulation). Similar reductions for Niaspan® and immediate-
release nicotinic acid occurred for LDL-cholesterol (–12% 
change for each formulation) and triglycerides (–15% and 
–17%, respectively), with no signiﬁ  cant differences between 
these groups.
Two other double-blind, placebo-controlled trials evalu-
ated the relationship between the dosage of Niaspan® given 
as monotherapy and changes in lipid parameters. One study 
involved randomization of patients with dyslipidemia to 
placebo (n = 44) or Niaspan® (n = 87), with daily doses 
increased from 500 mg to 3000 mg at intervals of 4 weeks 
(Goldberg et al 2000). Changes in lipid parameters in the 
placebo group were minimal. In contrast, treatment with all 
doses of Niaspan® was associated with signiﬁ  cant increases 
in HDL-cholesterol relative to placebo, up to a maximum 
increase of about 30% relative to baseline at doses of 2500–
3000 mg. The marked and signiﬁ  cant decreases in triglyc-
erides and LDL-cholesterol evident in Figure 2 are typical 
effects of nicotinic acid and may provide useful additional 
beneﬁ  ts on the overall lipid proﬁ  le. The second evaluation of 
different doses of Niaspan® monotherapy was a randomized 
comparison of Niaspan® 1000 mg (n = 41), Niaspan® 2000 mg 
(n = 41) and placebo (n = 40), each administered for 16 weeks 
to patients with hypercholesterolemia (Morgan et al 1996). 
Percentage changes from baseline in HDL-cholesterol with 
these treatments were 17%, 23%, and 4%, respectively. Cor-
responding changes in triglycerides were –21%, –29%, and 
3%, respectively, and changes in LDL-cholesterol were –6%, 
–14%, and 0%, respectively. Changes in all parameters at 
either dose were signiﬁ  cant relative to placebo (p   0.05). 
Most of these studies also demonstrated significant 
reductions in the atherogenic lipoprotein, Lp(a), which is 
Figure 2 Dose-related effect of Niaspan® (500–3000 mg/day) on lipid parameters in a 25-week, double-blind, randomized trial in 131 patients with hyperlipidemia. *p < 0.05 
vs placebo. Effects of placebo have been omitted for clarity. Drawn from data presented by Goldberg et al (2000).Vascular Health and Risk Management 2007:3(4) 472
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little affected by other currently available lipid-modifying 
treatments. Table 2 shows the effects of Niaspan® on Lp(a) 
from randomized, controlled clinical trials.
Niaspan® – statin combination therapy
Statins remain the mainstay of lipid-modifying therapy 
according to current guidelines, but exert relatively little 
effect on HDL-cholesterol, as described above. Many patients 
will therefore require combination therapy with Niaspan® 
plus a statin to correct concomitant disturbances of LDL-
cholesterol and HDL-cholesterol metabolism. A retrospective 
study analyzed data from 66 dyslipidemic patients prescribed 
Niaspan® 1000 mg or 2000 mg for at least 4 weeks in addition 
to pre-existing statin therapy (Wolfe et al 2001). Increases in 
HDL-cholesterol after addition of Niaspan® to the regimen 
were similar to those for Niaspan® monotherapy, described 
above, with mean increases of 23% with the 1000 mg dose 
and 27% for the 2000 mg dose. Additional reductions in 
LDL-cholesterol, of 8% and 31%, respectively vs statin 
alone, and in triglycerides, of 24% and 27% vs statin alone, 
were also observed. Larger increases in HDL-cholesterol 
were observed in patients with HDL-cholesterol  1.0 mmol/
L (40 mg/dL) at baseline. 
Double-blind, randomized, placebo-controlled, dose-
ranging evaluations of various combinations of Niaspan® 
(500–2500 mg) and a statin (lovastatin 10–40 mg) conﬁ  rm 
these observations (Hunninghake et al 2003; Insull et al 
2004). Dose-related increases in HDL-cholesterol occurred 
with increases in the dose of Niaspan® and additional 
reductions in LDL-cholesterol occurred when Niaspan® 
2000 mg was combined with lovastatin 40 mg, relative to 
this dose of statin plus placebo. A third trial (the ADvicor 
Versus Other Cholesterol-Modulating Agents Trial Evalu-
ation [ADVOCATE] Study) was conducted in 315 hyper-
cholesterolemic men or women with HDL-cholesterol  1.2 
mmol/L ( 45 mg/dL) or  1.3 mmol/L ( 50 mg/dL), 
respectively (Bays et al 2003). Patients were randomized to 
receive open-label Niaspan® – lovastatin combinations (doses 
up to 1000 mg/40 mg or 2000 mg/40 mg) or monotherapy 
with simvastatin (10–40 mg) or atorvastatin (10–40 mg) 
for 16 weeks. Larger increases in HDL-cholesterol were 
observed with Niaspan® – lovastatin 1000 mg/40 mg (+17%) 
and 2000 mg/40 mg (+32%), relative to atorvastatin 40 mg 
(+6%) or simvastatin 40 mg (+7%). 
Addition of the cholesterol absorption inhibitor, 
ezetimibe, increases the efﬁ  cacy of statins on additional 
lowering of LDL-cholesterol (Robinson and Davidson 2006). 
The efﬁ  cacy of this combination was compared with that of 
Niaspan® – statin combinations in 292 patients indicated for 
management of LDL-cholesterol according to US cardio-
vascular management guidelines in a 12-week, randomized 
trial (McKenney et al 2006). Reductions in LDL-cholesterol 
were similar between treatments, but Niaspan®-rosuvastatin, 
and Niaspan® – atorvastatin regimens were more effective 
in increasing HDL-cholesterol and in reducing triglycerides, 
compared with simvastatin in combination with ezetimibe 
or rosuvastatin monotherapy (Figure 3). 
Dyslipidemia requires lifelong management. The long-
term effects of Niaspan®, titrated towards a maximum dose 
of 3000 mg, were observed for up to 96 weeks in patients 
with dyslipidemia, some of whom were previously enrolled in 
short-term studies (Capuzzi et al 1998; Guyton and Capuzzi 
1998). Patients receiving Niaspan® at a dose of 2000 mg or 
less could also receive a statin or a bile acid sequestrant. 
Figure 4 shows effects on principal lipid parameters in 
Niaspan® – treated patients with or without additional statin 
treatment (the median dose of Niaspan® was 2000 mg in 
either group). Effects on HDL-cholesterol were essentially 
Table 2 Effects of Niaspan® on lipoprotein (a) (Lp(a)) in controlled clinical trials
Study  Duration (weeks)  Target dose of Niaspan® (mg)  Mean change in Lp(a) (%)
     Niaspan® Comparator
Morgan et al 1996  12  2000  –27†  0 (placebo)
Knopp et al 1998  16  1500  –24.7*  2.2 (placebo)
Grundy et al 2002  16  1500  –12  3 (placebo)
Bays et al 2003  16  2000  –21a,* 0  (atorvastatin)
         –2 (simvastatin)
Grundy et al 2004  20  1500  –21*  –6 (fenoﬁ  brate)
McKenney et al 2006  12  1000  –7b,*  8 (simvastatin + ezetimibe)
     –5c,* 11  (rosuvastatin)
Notes: Studies evaluating Niaspan® at target doses within its therapeutic dose range (2000 mg/day) are shown. Where more than one dose was evaluated, the largest effect 
on Lp(a) is shown. Signiﬁ  cant (p < 0.05 or better) vs *comparator or †baseline. Some trials involved combination of Niaspan® with asimvastatin, batorvastatin, or crosuvas-
tatin. Signiﬁ  cance in the study of McKenney et al (2006) refers to an ANOVA across all four treatments (Niaspan® + atorvastatin, Niaspan® + rosuvastatin, simvastatin + 
ezetimibe, and rosuvastatin monotherapy).Vascular Health and Risk Management 2007:3(4) 473
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identical between groups, with additional reductions in LDL-
cholesterol and triglycerides arising from statin treatment. 
Efﬁ  cacy in patients with cardiometabolic 
comorbidities
Patients with cardiometabolic comorbidities, such as type 
2 diabetes or the metabolic syndrome, are at markedly 
increased risk of adverse cardiovascular outcomes (Isomaa 
et al 2001) and require prompt correction of dyslipidemia. 
The Assessment of Diabetes Control and EValuation 
of the Efﬁ  cacy of Niaspan® Trial (ADVENT) involved 
randomization of 146 type 2 diabetes patients with the ath-
erogenic dyslipidemia phenotype (low HDL-cholesterol and/
or hypertriglyceridemia) to receive double-blind treatment 
with Niaspan® 1000 mg, Niaspan® 1500 mg or placebo for 
16-weeks (Grundy et al 2002). Mean increases in HDL-
cholesterol at study end in the Niaspan® 1000 mg and 1500 
mg groups were 19% and 24%, respectively, which were sig-
niﬁ  cant (p   0.05) compared with small changes observed 
on placebo. A further 20-week, double-blind, randomized 
evaluation compared Niaspan® 1000 mg and Niaspan® 1500 
mg, each combined with lovastatin 40 mg, with fenoﬁ  brate 
in patients with atherogenic dyslipidemia (HDL-cholesterol 
 1.0 mmol/L [ 40 mg/dL] in men or  1.3 mmol/L 
[ 50 mg/dL] in women and triglycerides  1.7 mmol/L 
[150 mg/dL]) (Grundy et al 2004). The mean increase in HDL 
cholesterol was greater with Niaspan® relative to fenoﬁ  brate 
(26% vs 12%; p   0.05). The additional potentially 
beneﬁ  cial effects on lipid parameters other than HDL-
cholesterol described above for non-diabetic populations 
were also observed in both of these studies.
A retrospective analysis presented in abstract form 
reviewed data from 757 subjects who had received Niaspan® in 
combination with lovastatin, of whom 347 had the metabolic 
syndrome (National Cholesterol Education Program criteria) 
(McGovern et al 2004). Mean increases in HDL-cholesterol 
were similar in patients with and without the metabolic 
syndrome (36% vs 32%), as were reductions in LDL-
cholesterol (–42% and –45%). A slightly larger decrease 
in triglycerides occurred in patients with vs those without 
the metabolic syndrome (–47% vs –32%, p   0.05).
Lipid sub-proﬁ  les
The atherogenic dyslipidemia phenotype is characterized 
by a shift in the lipoprotein sub-class distribution towards 
Figure 3 Comparison of effects on lipids of combinations of nicotinic acid with a statin in comparison with a combination of a statin with ezetimibe or rosuvastatin mono-
therapy in a 12-week, open-label, randomized trial in 292 patients indicated for LDL-cholesterol lowering therapy. Patients received rosuvastatin (20–40 mg), rosuvastatin 
plus Niaspan® (10/1000 mg or 20/1000 mg), atorvastatin plus Niaspan® (20/1000 mg or 40/2000 mg), or simvastatin plus ezetimibe (20/10 mg or 40/10 mg). Signiﬁ  cance 
values are from ANOVA across groups. Drawn from data presented by McKenney et al (2006). 
Figure 4 Long-term (96 weeks) effects of Niaspan® (up to 3000 mg/day) on the 
lipid proﬁ  le in patients with dyslipidemia, with (n = 122) or without (n = 225) 
concomitant statin administration. Drawn from data presented by Guyton and 
Capuzzi (1998). Vascular Health and Risk Management 2007:3(4) 474
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small, dense particles (Goldberg 2001). These are believed 
to be more atherogenic than larger, more buoyant particles, 
particularly in the case of small, dense LDL (Goldberg 2001). 
Thus, an increase in lipoprotein particle size is generally con-
sidered to represent a reduction in atherogenicity. A study in 
60 patients with primary hypercholesterolemia who received 
Niaspan® 1000 mg or 2000 mg for 12 weeks demonstrated an 
increased proportion of larger HDL particles, and a reduced 
proportion of small, dense LDL particles (Morgan et al 2003). 
Other studies have demonstrated increases in the HDL2 sub-
fraction with Niaspan® given either as monotherapy (Knopp 
et al 1998; Goldberg et al 2000) or in combination with a 
statin (Van et al 2002; Bays and McGovern 2003).
Tolerability and safety of Niaspan®
Flushing is the main tolerability issue with nicotinic acid, 
including Niaspan®. The frequency of ﬂ  ushing with Niaspan® 
and immediate-release nicotinic acid was evaluated during 
8 weeks of double-blind treatment (Kos Pharmaceuticals/
Merck KGaA, data on ﬁ  le). These data indicated that 72% 
of patients ﬂ  ushed once with Niaspan®, ie, about 28% of pa-
tients did not report ﬂ  ushing. About 20% of patients ﬂ  ushed 
6 times, ie, about 80% ﬂ  ushed 5 times or less. The frequency 
of ﬂ  ushing was lower with Niaspan® than with immediate-
release nicotinic acid. In general, ﬂ  ushing tends to decrease 
during continued treatment with Niaspan®. Flushing can be 
minimized by taking Niaspan® at bedtime with a low-fat 
snack, and by avoiding spicy foods or alcohol close to the 
time of Niaspan® intake. Analgesic doses of a non-steroidal 
anti-inﬂ  ammatory agent are effective in terminating ﬂ  ushing 
episodes. 
Niaspan® is not associated with significant hepatic 
toxicity. Long-term (up to 96 weeks) evaluations of Niaspan® 
monotherapy (n = 517) or Niaspan® – statin combinations 
demonstrated an incidence of liver function test abnormali-
ties of  1%. Similarly, extensive clinical experience with 
Niaspan® in the USA conﬁ  rms that the potential of Niaspan® 
to induce rhabdomyolysis is minimal, whether it is prescribed 
alone or in combination with a statin. A review of adverse 
event reporting to the US Food and Drug Administration sup-
ports a beneﬁ  cial safety proﬁ  le for Niaspan® (Al-Sheikh et al 
2005). The incidence of reports of hepatic adverse events with 
Niaspan® (2 per million prescriptions) was signiﬁ  cantly lower 
than that for commonly used statins, or ﬁ  brates. Similarly the 
incidence of side-effects in musculature was generally similar 
to, or lower than those reported for these agents. 
Double-blind trials in type 2 diabetic populations have 
shown that the effects of Niaspan® on glycemia are minimal, 
with changes in HbA1C of  0.3% units that can be accom-
modated by alterations to the antidiabetic regimen (Grundy 
et al 2002, 2004). However, it is theoretically possible that 
exacerbation of pre-diabetic dysglycemia might precipitate 
a diagnosis of clinical type 2 diabetes or the metabolic 
syndrome. The effects of Niaspan® on fasting glucose in 
non-diabetic subjects were similar to those of immediate-
release Niaspan® in a comparative, randomized trial, with 
increases of 4%–5% from baseline at a total dose of nicotinic 
acid of 1500 mg/day (Knopp et al 1998). Comparable, rela-
tively minor increases in fasting glucose were observed in 
other randomized evaluations of Niaspan® in dyslipidemic 
patients who were non-diabetic or had well-controlled diabe-
tes (Morgan et al 1996; Capuzzi et al 1998), although other 
studies found no effect, or a transient effect, of Niaspan® on 
fasting glucose in comparable populations (Goldberg et al 
2000; Kashyap et al 2002). One study evaluated Niaspan® 
in patients with HIV managed with antiretroviral therapy, 
which often is associated with insulin resistance and associ-
ated comorbidities reminiscent of the metabolic syndrome 
(Sweet 2005). This trial included 23 pre-diabetic patients 
within its overall population: in this sub-group, there were 
no cases of prolonged fasting hyperglycemia, and only one 
case of post-challenge hyperglycemia (measured using an 
oral glucose tolerance test) after 44 weeks of treatment 
with Niaspan® at doses up to 2000 mg. In conclusion, while 
minor increases in blood glucose are common with Niaspan® 
or other nicotinic acid preparations, the overall impact on 
cardiovascular risk is likely to be minor compared with the 
potential anti-atherosclerotic beneﬁ  ts of Niaspan®, which are 
described later in this review.
Nicotinic acid also suppresses free fatty acid (FFA) pro-
duction, which contributes to its effects on the lipid proﬁ  le, 
but a rebound in FFA levels often occurs after treatment with 
immediate-release nicotinic acid (Chapman 2006). We are 
unaware if such a rebound occurs with Niaspan®, and clinical 
evaluation of this phenomenon is warranted.
The NAUTILUS study: a recent 
multicentre evaluation of Niaspan® 
in a real-life clinical setting
Rationale and design of NAUTILUS
The studies described above provide a detailed account of the 
efﬁ  cacy, safety and tolerability of Niaspan®, deﬁ  ned mainly 
within the controlled environments of double-blind, random-
ized trials. However, the management of dyslipidemia takes 
place mainly in the routine, usual-care setting. The multi-Vascular Health and Risk Management 2007:3(4) 475
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ceNtre, open, uncontrolled sAfety and tolerability stUdy of a 
modiﬁ  ed-release nicoTinic acId formuLation in sUbjects with 
dyslipidemia and low HDL-cholesterol (NAUTILUS) trial 
was designed to evaluate Niaspan® in a realistic environment 
relevant to the day-to-day care of patients with dyslipidemia, 
and is thus described separately here. The main purpose of 
NAUTILUS was to evaluate the safety and tolerability of 
Niaspan®. Effects on lipid parameters were also measured.
NAUTILUS was a multicenter (112 centers), evaluation 
of open-label Niaspan®, administered for 15 weeks (Vogt 
et al 2006a). Eligible patients had dyslipidemia uncon-
trolled by 4 weeks of treatment with diet and also had low 
HDL-cholesterol ( 1.0 mmol/L [40 mg/dL] in men and 
 1.2 mmol/L [50 mg/dL] in women). Diabetes was not 
an exclusion criterion, although patients with uncontrolled 
diabetes were excluded. Study treatment was titrated towards 
a maximum of 2000 mg in stages over 12–15 weeks of treat-
ment, depending on tolerability responses. Down-titration 
was allowed to resolve tolerability issues, though reduction 
of the Niaspan® dose to below 750 mg, or failure to receive 
at least one dose of Niaspan® 1000 mg resulted in exclusion 
from the trial. 
Main results of NAUTILUS
A total of 566 patients received treatment. The study popula-
tion was at elevated cardiovascular risk, on average, with 80% 
having at least one cardiovascular comorbidity (hypertension 
or vascular disease) and 58% having diabetes. On average, 
patients at baseline had low HDL-cholesterol (mean HDL-cho-
lesterol was 0.86 mmol/L [33 mg/dL] in men and 0.99 mmol/L 
[38 mg/dL] in women) and hypertriglyceridemia (mean tri-
glycerides were 2.91 mmol/L [258 mg/dL]), consistent with 
study inclusion criteria. LDL-cholesterol was not markedly 
elevated at baseline, with mean values of 2.80 mmol/L [108 
mg/dL] in men and 3.24 mmol/L [125 mg/dL] in women.
Niaspan® was generally well tolerated, apart from 
ﬂ  ushing, the principal tolerability issue with nicotinic acid. 
Flushing was reported by 42.0% of patients, although most 
episodes were mild or moderate in severity. Consistent with 
these observations, the incidence of treatment withdrawal 
for ﬂ  ushing was low (9.7%) and only a minority of patients 
ﬂ  ushed more than ﬁ  ve times (Figure 5), consistent with 
previous experience with Niaspan®, as described above. The 
incidence of all-cause serious adverse events was also low 
(3.7%), and was related to ﬂ  ushing in 0.2% of patients. There 
was no serious hepatic or muscle toxicity.
Mean increases from baseline in HDL-cholesterol in 
men and women were 22.4% and 28.1%, respectively, with 
corresponding decreases in triglycerides of –10.6% and 
–17.1% (Figure 6).
Results in clinically important patient 
subgroups
Subgroup analyses in the NAUTILUS trial included 
stratification of patients according to gender, the presence 
of diabetes, metabolic syndrome, hypercholesterolemia 
or isolated low HDL-cholesterol, receipt/non-receipt of 
concomitant statin treatment, and age (Vogt et al 2006a, 
b, c, d). The incidence of flushing or other adverse events 
did not vary to a clinically significant extent according 
to age, statin use, or diabetes (flushing was not analyzed 
separately in the other subgroups listed above). However, 
older patients were somewhat more likely to withdraw 
due to flushing (15% vs 7%). 
Figure 6 shows effects on the main indices of atherogenic 
dyslipidemia (HDL-cholesterol and triglycerides) from sub-
group analyses. Robust improvements in either parameter 
were observed in all subgroups.
Anti-atherosclerotic effects 
of Niaspan® 
The Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol (ARBITER 2) study, and 
its follow-up study (ARBITER 3) were designed to explore 
whether Niaspan® co-administered with a statin expresses the 
anti-atherogenic actions demonstrated by immediate-release 
nicotinic acid-statin combinations in the HATS and other 
trials, described above (Taylor et al 2004, 2006). Patients 
eligible for these studies had low HDL-cholesterol ( 1.2 
Figure 5 Flushing with Niaspan® in the NAUTILUS trial, a 15-week evaluation of 
Niaspan® at doses up to 2000 mg/day in 566 patients with dyslipidemia and low 
HDL-cholesterol managed in the usual care setting. Reproduced with permission 
from Vogt A, Kassner U, Hostalek U, et al 2006. Evaluation of the safety and toler-
ability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS 
study. Curr Med Res Opin, 22:417–25.Vascular Health and Risk Management 2007:3(4) 476
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mmol/L [46 mg/dL]) despite existing treatment with a statin, 
and had coronary artery disease. 
The ARBITER 2 trial was a randomized, double-
blind, parallel-group study, in which a moderate dose of 
Niaspan® (1000 mg) was compared with placebo, each 
being added to pre-existing statin treatment for 1 year. 
ARBITER 3 was an open-label extension to ARBITER 
2. Of 78 patients who completed 1 year of treatment with 
Niaspan® in ARBITER 2, 69 continued on this treatment 
for a further year, with 57 patients completing the study 
(Figure 7). Of 71 patients who received placebo in AR-
BITER 2, 61 switched to Niaspan® and 47 completed a 
year of Niaspan® treatment in ARBITER 3 (Figure 7). 
B-mode ultrasound was used in both phases of the study 
to measure carotid intima-media thickness (CIMT), an 
accepted and validated surrogate marker for the overall 
burden of atherosclerosis (Hodis et al 1998). 
One year of treatment with Niaspan® in ARBITER 
2 increased mean HDL-cholesterol from 1.0 mmol/L 
(39 mg/dL) to 1.2 mmol/L (47 mg/dL; p   0.001), and 
decreased triglycerides from 1.7 mmol/L (154 mg/dL) to 
1.5 mmol/L (134 mg/dL; p = 0.009), while no change in 
either parameter occurred in the placebo group. The mean 
value of HDL-cholesterol at the end of ARBITER 3 was 
similar in groups who had previously received placebo 
or Niaspan® in ARBITER 2 (1.25 mmol/L [48.5 mg/dL] 
and 1.26 mmol/L [48.6 mg/dL], respectively). LDL-
cholesterol was unchanged by Niaspan®, which is not 
surprising as this parameter was already well controlled 
in this statin-treated population (mean baseline value 2.3 
mmol/L [87.6 mg/dL]).
Effects on atherosclerosis in the ARBITER trials 
are shown in Table 3. In ARBITER 2, atherosclerosis 
progressed significantly in patients randomized to re-
ceive placebo, while no significant progression of ath-
erosclerosis occurred in the Niaspan® group over 1 year 
of treatment. In ARBITER 3, atherosclerosis regressed 
significantly in patients switched from placebo to Nias-
Figure 6 Mean changes in HDL-cholesterol and triglycerides in subgroups of the NAUTILUS population based on gender, presence/absence of the metabolic syndrome 
(MS), hypercholesterolemia (HC), isolated low HDL-cholesterol (ILH), receipt/non-receipt of statins, presence/absence of diabetes mellitus (DM), and age. Drawn from data 
presented by Vogt et al 2006a, b, c, d.Vascular Health and Risk Management 2007:3(4) 477
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pan® and in patients who continued on Niaspan® for 
another 12 months of treatment. Pooling the data from 
ARBITER 2 and ARBITER 3 showed that 12 months of 
Niaspan® in either trial was associated with significant 
regression of atherosclerosis, relative to 12 months of 
placebo. Atherosclerosis also regressed to a significant 
extent relative to placebo in 62 patients with type 2 dia-
betes or the metabolic syndrome who received Niaspan® 
for 12 or 24 months. 
Changes in CIMT correlated significantly and in-
versely with changes in HDL-cholesterol (p = 0.002), 
and multivariate analysis showed that changes in CIMT 
were signiﬁ  cantly and independently related to changes 
in HDL-cholesterol, but not to changes in triglycerides or 
LDL-cholesterol. Thus, the ARBITER 2 and ARBITER 3 
trials demonstrate that increased HDL-cholesterol during 
treatment with Niaspan® and a statin was associated with 
clinically signiﬁ  cant anti-atherogenic beneﬁ  ts in patients 
with coronary artery disease.
Looking ahead: evaluating 
the effects of Niaspan® on clinical 
outcomes
The ARBITER 2 and ARBITER 3 studies were too small to 
conﬁ  rm that the clinical outcome beneﬁ  ts observed with a 
combination of immediate-release nicotinic acid and a statin 
in the HATS trial translate to Niaspan®-based combination 
therapy. The double-blind, randomized, multicenter Athero-
thrombosis Intervention in Metabolic Syndrome with Low 
HDL-C/High Triglyceride and Impact on Global Health 
Outcomes trial (AIM-HIGH) will address this question. The 
study hypothesis is that the clinical cardiovascular event rate 
in patients randomized to Niaspan® plus simvastatin will be 
lower than that in patients randomized to simvastatin alone 
during 6 years of treatment, despite levels of LDL-cholesterol 
being similar in each group.
The study is jointly funded by the US National Institutes of 
Health and Kos Pharmaceuticals Inc, and is currently recruit-
ing patients. Eligible patients have atherogenic dyslipidemia, 
characterized by low HDL-cholesterol, deﬁ  ned as  1.03 
mmol/L ( 40 mg/dL) for men and  1.29 ( 50 mg/dL) for 
women (these values change to  1.08 mmol/L [42 mg/dL] 
and  1.37 mmol/L [53 mg/dL], respectively, if already on a 
statin) and triglycerides  1.7 mmol/L (150 mg/dL). Inclusion 
criteria for LDL-cholesterol vary according to statin treatment. 
The primary study endpoint will be a composite of coronary 
heart disease death, nonfatal myocardial infarction, ischemic 
stroke, or hospitalization for high-risk acute coronary syn-
drome with objective evidence of ischemia.
Table 3 Effects of Niaspan® on atherosclerosis in the ARBITER 2 study and in a pooled analysis of data from the ARBITER 2 and ARBITER 3 studies
 Niaspan®   Placebo 
  Mean change in   p  Mean change in  p
 CIMT  (mm)    CIMT(mm)
ARBITER 2  0.014 ± 0.011  0.23  0.044 ± 0.011   0.001
ARBITER 3       
Patients switching from placebo to Niaspan® (n = 47)  –0.095 ± 0.019   0.001 –  –
Patients continuing on Niaspan® for additional 12 months (n = 57)  –0.041 + 0.021  0.001  –  –
Pooled analysis of ARBITER 2 and ARBITER 3 
First 12 months of Niaspan® in ARBITER 2 or ARBITER 3 (n = 125)  –0.027 ± 0.011   0.001 –  –
12–24 months of Niaspan® in patients with type 2 diabetes or
 the metabolic syndrome (n = 62)  –0.046 ± 0.131   0.001 –  –
Notes: Signiﬁ  cance values for ARBITER 2 are relative to baseline, while signiﬁ  cance values for ARBITER 3 or the pooled analysis of ARBITER 2 and ARBITER 3 are relative 
to the placebo phase of ARBITER 2. Compiled from data presented by Taylor et al (2004, 2006).
Abbreviations: CIMT, carotid intima-media thickness.
Figure 7 Treatment assignments in the double-blind, randomized, ARBITER 2 
study and its open-label follow-up study, ARBITER 3. Numbers of patients shown 
are those completing each phase. The duration each phase trial was 1 year; the 
Niaspan® daily dose was 1000 mg. Adapted with permission from Taylor AJ, Lee HJ, 
Sullenberger LE. 2006. The effect of 24 months of combination statin and extended-
release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin, 
22:2243–50.Vascular Health and Risk Management 2007:3(4) 478
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Summary and conclusions
The burden of cardiovascular morbidity and mortal-
ity remains unacceptably high despite widespread use of 
statins to control LDL-cholesterol. Low HDL-cholesterol 
is common among patients managed for dyslipidemia and 
represents an important and under treated source of elevated 
cardiometabolic risk. Nicotinic acid, the most powerful 
agent currently available for the correction of low HDL-
cholesterol, has been shown in well-designed clinical trials 
to inhibit the progression of atherosclerosis and to reduce 
cardiovascular event rates in patients at high risk of adverse 
cardiovascular outcomes. Niaspan® provides a practical 
and convenient means of administering nicotinic acid, with 
once-daily administration and a superior tolerability and/or 
safety proﬁ  le compared with other formulations of nicotinic 
acid. The ARBITER 2 and ARBITER 3 studies suggested 
that the antiatherogenic beneﬁ  ts of nicotinic acid translate to 
Niaspan®, and the AIM-HIGH study will deﬁ  ne the cardio-
protective potential of Niaspan®-statin combination therapy 
relative to statin monotherapy. 
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